More rumors on potential Onyx acquisition
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) and Amgen Inc. (NASDAQ:AMGN) declined to comment on Wednesday on a Reuters story that said Onyx granted Amgen and other potential buyers access to data from an ongoing trial of multiple myeloma drug Kyprolis carfilzomib. Last week, Bloomberg reported that talks for the cancer company's rumored acquisition by Amgen were held up over a dispute related to data from a trial designed to support European approval of Kyprolis (see BioCentury Extra, Aug. 15).
Earlier this month, media reports said Amgen raised its bid to acquire Onyx to $130 per share in cash, or about $9.5 billion. Last month, Onyx's board rejected an unsolicited offer from Amgen to acquire Onyx for $120 per share in cash, or about $8.7 billion. However, at the time the company said it was open to additional offers. ...